Frazier Life Sciences IX L.P. 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-06 10:26 am Purchase |
2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Frazier Life Sciences IX L.P. | 1,587,527 4.200% |
170,370 (+12.02%) |
Filing |
| 2022-01-28 2:09 pm Sale |
2021-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Frazier Life Sciences IX L.P. | 1,417,157 6.900% |
-500,000 (-26.08%) |
Filing |
| 2020-10-23 1:40 pm Purchase |
2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Frazier Life Sciences IX L.P. | 1,917,157 9.500% |
1,917,157 (New Position) |
Filing |